NasdaqGS:AGIOBiotechs
Agios Pharmaceuticals (AGIO) Heavy EPS Loss Tests Growth‑Led Bullish Narratives Heading Into Q1 2026
Agios Pharmaceuticals (AGIO) has opened Q1 2026 earnings season with a recent run of quarterly results that show total revenue of $19.97 million in Q4 2025 and a basic EPS loss of $1.85, alongside trailing twelve month revenue of $54.03 million and a basic EPS loss of $7.12. Over the past six reported quarters, the company has seen quarterly revenue move between $8.73 million and $19.97 million, while basic EPS has ranged from a loss of $1.55 to a one off positive print of $16.65, giving...